Tiffany Beauvais
Nantes, 44000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
PD-1 and TIGIT coexpression enables selective enrichment of clonally expanded tumor-reactive CD8 T cells for melanoma TIL therapy.
Journal: Journal of translational medicine
Published: April 15, 2026
Systematic identification of lincRNA-derived immunogenic peptides in melanoma.
Journal: Oncoimmunology
Published: August 02, 2025
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes.
Journal: Oncoimmunology
Published: July 10, 2024
Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.
Journal: Oncoimmunology
Published: July 09, 2021
Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients.
Journal: Cancer immunology, immunotherapy : CII
Published: January 05, 2021
Low Levels of Natural Anti-α-N-Acetylgalactosamine (Tn) Antibodies Are Associated With COVID-19.
Journal: Frontiers in microbiology
Published: December 14, 2020
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
Journal: Journal for immunotherapy of cancer
Published: October 25, 2020
Mycolactone toxin induces an inflammatory response by targeting the IL-1β pathway: Mechanistic insight into Buruli ulcer pathophysiology.
Journal: PLoS pathogens
Published: June 09, 2020
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Journal: Journal for immunotherapy of cancer
Published: January 05, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026